

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 31/19, 31/235, 31/57 // (A61K 31/57, 31:235, 31:19)	A1	(11) International Publication Number: WO 97/15298 (43) International Publication Date: 1 May 1997 (01.05.97)
(21) International Application Number: PCT/EP96/04391 (22) International Filing Date: 10 October 1996 (10.10.96) (30) Priority Data: 9521696.6 23 October 1995 (23.10.95) GB (71) Applicant (for all designated States except US): BAYER AKTIENGESELLSCHAFT [DE/DE]; D-51368 Leverkusen (DE). (72) Inventors; and (75) Inventors/Applicants (for US only): BURCHARDT, Elmar-Reinhold [DE/DE]; Dorfstrasse 28, D-58239 Schwerte (DE). MÜLLER-PEDDINGHAUS, Reiner [DE/DE]; Klutstein 22a, D-51467 Bergisch-Gladbach (DE). ABRAM, Trevor, S. [GB/GB]; 214 Marlow Bottom, Marlow, Buckinghamshire SL7 3PR (GB). (74) Common Representative: BAYER AKTIENGESELLSCHAFT; D-51368 Leverkusen (DE).	(81) Designated States: AU, BG, BR, BY, CA, CN, CZ, EE, HU, IS, JP, KE, KP, KR, LT, LV, MX, NO, NZ, PL, RO, RU, SG, SI, SK, UA, US, VN, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report.</i>	
(54) Title: COMBINATION OF LTD, RECEPTOR ANTAGONISTS WITH GLUCOCORTICOSTEROIDS (57) Abstract The invention relates to a combination of glucocorticosteroids with LTD ₄ receptor antagonists in medicaments for the treatment of inflammatory disorders, especially of the airways.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

Combination of LTD₄ receptor antagonists with glucocorticosteroids

5 The present invention relates to the combination of LTD₄ receptor antagonists with glucocorticosteroids (GCSs), in particular for the treatment of acute and chronic inflammatory disorders.

It is known that GCSs are used, because of their potent antiinflammatory effect, in the treatment of a large number of widely different inflammatory disorders.

10 GCSs modulate protein biosynthesis and are described as selective regulators of gene transcription. GCSs suppress the synthesis of cytokines and growth factors in inflammatory cells and the expression of adhesion molecules on their surface. It is likewise known that protein biosynthesis of other gene products such as, for example, of lipocortin and of IL-6 is induced.

15 Lipocortins are described as proteins regulating the activity of phospholipase A₂, which is responsible for the release of free fatty acids from phospholipid-containing membranes. Lipocortins show an antiinflammatory effect in vitro and in vivo. One of the most important free fatty acids, arachidonic acid, is metabolized by the enzymatic action of cyclooxygenases and lipoxygenases, especially 5-lipoxygenase, and converted into a variety of proinflammatory mediators.

20 This is why it has been assumed hitherto that the antiinflammatory effect of GCSs derives indirectly from the PLA₂-inhibitory effect of lipocortins which are induced by GCSs.

It is additionally known that LTD₄ receptor antagonists are used for the treatment of inflammatory, especially of allergic asthma.

25 On account of the mode of action hitherto described for the GCSs on eicosanoid release and the effect reported to date of the LTD₄ receptor antagonists on inflammations mediated by cysteinyl-leukotrienes, the additive effects of the combination of the two substances were completely surprising.

30 It has been found that the combination of LTD₄ receptor antagonists with GCSs is particularly suitable, on account of their surprising synergistic effect or for the

treatment of acute and chronic inflammatory processes, in particular for the treatment of inflammatory airway disorders such as asthma.


Within the scope of the invention, GCS represents the customary glucocorticosteroids such as, for example, amcinonide, beclomethasone dipropionate, betamethasone, betamethasone acetate, betamethasone benzoate, betamethasone dipropionate, betamethasone sodium phosphate, betamethasone valerate, budesonide, carbenoxolone sodium, clocortolone acetate, clocortolone pivalate, cloprednol, corticotropin (injection), corticotropin (repository), corticotropin zinc hydroxide, cortisone acetate, cortivazole, descinolone acetonide, dexamethasone, dexamethasone sodium phosphate, diflucortolone, diflucortolone pivalate, flucoronide, flumethasone, flumethasone pivalate, flunisolide, fluocinolone acetonide, fluocinonide, fluocortolone, fluocortolone caproate, fluorometholone, fluperolone acetate, fluprednisolone, fluprednisolone valerate, flurandrenolide, formocortal, fluticasone, hydrocortisone, hydrocortisone acetate, hydrocortisone buteprate, hydrocortisone butyrate, hydrocortisone cypionate, hydrocortisone sodium phosphate, hydrocortisone sodium succinate, hydrocortisone valerate, medrysone, methylprednisolone, methylprednisolone acetate, methylprednisolone sodium phosphate, methylprednisolone sodium succinate, nivazole, paramethasone acetate, prednicarbate, prednisolone, prednisolone acetate, prednisolone hemisuccinate, prednisolone sodium phosphate, prednisolone sodium succinate, prednisilone tebutate, prednisone, prednival, ticabesone propionate, tralonide, triamcinolone, triamcinolone acetonide, triamcinolone acetonide sodium phosphate, triamcinolone diacetate and triamcinolone hexacetonide.

GCSs which are preferably mentioned are beclomethasone dipropionate, betamethasone, betamethasone acetate, betamethasone benzoate, betamethasone dipropionate, betamethasone sodium phosphate, betamethasone valerate, budesonide, cortisone acetate, dexamethasone, dexamethasone sodium phosphate, diflucortolone, diflucortolone pivalate, flumethasone, flumethasone pivalate, hydrocortisone, hydrocortisone acetate, hydrocortisone buteprate, hydrocortisone butyrate, hydrocortisone cypionate, hydrocortisone sodium phosphate, fluticasone, hydrocortisone sodium succinate, hydrocortisone valerate, methylprednisolone, methylprednisilone acetate, methylprednisolone sodium phosphate, methylprednisolone sodium succinate, paramethasone acetate, prednisolone, prednisolone acetate, prednisolone hemisuccinate, prednisolone sodium phosphate, prednisolone

sodium succinate, prednisolone tebutate, prednisone and triamcinolone. Beclo-methasone and budesonide are particularly preferred.

LTD₄ receptor antagonists within the scope of the invention are all substances which block the biological effect of the cysteinyl-leukotrienes LTC₄ and LTD₄ at their receptor (CysLT1).

In this connection, preferred compounds are those of the general formula



in which

X and Y denote, identically or differently, sulphur, sulfoxide, sulphone, an alkylene chain, -SCH₂- or oxygen or a direct linkage,

W denotes -CH=CH- or -CH₂-CH₂-,

o denotes a number from 1 to 5,

A and B denote, identically or differently, carboxyl, carboxymethyl, tetrazolyl or tetrazolylmethyl or -CO₂R⁹ or -CH₂CO₂R⁹ or -CONR¹⁰R¹¹ or cyano,

n denotes a number from 1 to 10,

m denotes a number from 0 to 7,

T and Z denote, identically or differently, oxygen or a direct linkage, and

R², R³, R⁶ denote, identically or differently, hydrogen, alkyl, alkoxy, halogen, trifluoromethyl, trifluoromethoxy, cyano or nitro,

R^9 denotes lower alkyl and

R^{10} and R^{11} denote hydrogen, lower alkyl, alkylsulphonyl or arylsulphonyl, or they form together an alkylene chain to form a ring,

and the salts thereof.

5 Particularly preferred LTD_4 receptor antagonists are compounds of the formula (I) in which

X denotes sulphur, sulphone or a methylene group,

Y denotes sulphur, a methylene group, $-SCH_2-$ or a direct linkage,

W is $-CH=CH-$,

10 R^8 and R^3 denote H,

R^2 is H or F,

o is a number from 1, 2, 3 or 4,

n is a number from 2, 3, 4, 5 or 6,

m is a number from 0, 1 or 2,

15 T denotes oxygen or a direct linkage,


Z denotes oxygen or a direct linkage,

A denotes carboxyl or an ester thereof,

B denotes para-carboxyl or an ester thereof,

and the salts thereof.

20 Very particularly preferred LTD_4 receptor antagonists are those of the formula (Ia)



in which

R^1 and R^2 are identical or different and

represent hydrogen, a branched or straight-chain C_{1-6} -alkyl or a benzyl radical,
 5 appropriate isomers thereof, and salts thereof.

In view of the effect of GCSs an eicosanoid release and the effects of LTD_4 receptor antagonists on inflammation reaction mediated by cysteinyleukotriene, it is completely surprising to find a superadditive effect of the combinations according to the invention.

10 The compound of the formula (I), the processes for preparing it are described in the publications EP 494 621 and Bioorg. Med. Chem. Lett. (1993), 3(8), 1517-22.

The combination according to the invention of glucocorticosteroids with the LTD_4 receptor antagonists can be used, on account of its specific properties, for the treatment of acute, chronic, autoimmune or non-autoimmune inflammations.

15 The combination according to the invention furthermore opens up the possibility of a significant reduction in the effective dose of the glucocorticosteroids. This makes it possible to achieve a reduction in the dosedependent unwanted effects of the medicament.

20 GCS and LTD_4 receptor antagonists in the combination can be combined in one or second ratio depending on the action potency of the individual substances.

The combination according to the invention can be used both in human medicine and in veterinary medicine.

Suitable indications are the treatment and prevention of inflammatory disorders of the airway such as allergies/asthma, bronchitis, emphysema, shock lung, pulmonary hypertension, and of the liver, intestine, kidney, pancreas, heart, nose, mouth, ears, eyes, central nervous system, muscles, connective tissue and joints, inflammations/rheumatism and oedemas, thromboses and thromboembolisms, ischaemias (disturbances of peripheral, cardiac and cerebral blood flow), infarcts (myocardial, cerebral, intestinal and other tissues), angina pectoris, inflammatory vascular disorders, arteriosclerosis, in tissue transplants, postoperative inflammations as well as vasodilatation, vessel transplant, dermatoses such as psoriasis, inflammatory dermatoses and inflammatory processes during infectious diseases (parasites, viruses, bacteria, fungi and oncoses).

The novel combination can be converted in a manner known per se, using inert, non-toxic, pharmaceutically suitable vehicles or solvents, into the customary perenteral formulations such as, for example, lyophilisates and solutions. In these, the therapeutically effective combination should in each case be present in a concentration of about 0,5 to 90 % by weight, preferably from 5 to 70 % by weight, which is sufficient to reach the stated range of dosage.

The combination can be used orally, subcutaneously, intramuscularly, intravenously or topically as aerosol (lung), ointment/cream (skin) or solution (mucous membranes).

The abovementioned pharmaceutical compositions can be produced in a conventional way by known methods, for example with the ancillary substance(s) or vehicle(s).


However, it may, where appropriate, be advantageous to deviate from the stated amounts, in particular depending on the body weight and on the mode of administration, or on the individual behaviour towards the medicament, the type of formulation thereof and the time or interval over which administration takes place. Thus, it may be sufficient in some cases to deal with less than the abovementioned minimum amount, whereas in other cases the stated upper limit must be exceeded. When larger amounts are administered, it may be advisable to distribute these in several individual doses throughout the day.

Patent Claims

1. Combination of LTD₄ receptor antagonists with glucocorticosteroids (GCSs).
2. Combination according to Claim 1, characterized in that compounds of the
5 group consisting of amcinonide, beclomethasone dipropionate, betamethasone, betamethasone acetate, betamethasone benzoate, betamethasone dipropionate, betamethasone sodium phosphate, betamethasone valerate, budesonide, carbenoxolone sodium, clocortolone acetate, clocortolone pivalate, cloprednol, corticotropin (injection),
10 corticotropin (repository), corticotropin zinc hydroxide, cortisone acetate, cortivazole, descinolone acetonide, dexamethasone, dexamethasone sodium phosphate, diflucortolone, diflucortolone pivalate, flucclorinide, flumethasone, flumethasone pivalate, flunisolide, fluocinolone acetonide, fluocinonide, fluocortolone, fluocortolone caproate, fluorometholone,
15 fluperolone acetate, fluprednisolone, fluprednisolone valerate, flurandrenolide, formocortol, fluticasone, hydrocortisone, hydrocortisone acetate, hydrocortisone buteprate, hydrocortisone butyrate, hydrocortisone cypionate, hydrocortisone sodium phosphate, hydrocortisone sodium succinate, hydrocortisone valerate, medrysone, methylprednisolone,
20 methylprednisolone acetate, methylprednisolone sodium phosphate, methylprednisolone sodium succinate, nivazole, paramethasone acetate, prednicarbate, prednisolone, prednisilone acetate, prednisolone hemisuccinate, prednisoline sodium phosphate, prednisolone sodium succinate, prednisiline tebutate, prednisone, prednival, ticabesone
25 propionate, tralonide, triamcinolone, triamcinolone acetonide, triamcinolone acetonide sodium phosphate, triamcinolone diacetate and triamcinolone hexacetonide, are employed as glucocorticosteroids.
3. Combination according to Claim 1, characterized in that compounds of the
30 series consisting of beclomethasone dipropionate, betamethasone, betamethasone acetate, betamethasone benzoate, betamethasone dipropionate, betamethasone sodium phosphate, betamethasone valerate, budesonide, cortisone acetate, dexamethasone, dexamethasone sodium phosphate, diflucortolone, diflucortolone pivalate, flumethasone, flumethasone pivalate, hydrocortisone, hydrocortisone acetate, hydrocortisone buteprate,

hydrocortisone butyrate, hydrocortisone cypionate, hydrocortisone sodium phosphate, fluticasone, hydrocortisone sodium succinate, hydrocortisone valerate, methylprednisilone, methylprednisilone acetate, methylprednisolone sodium phosphate, methylprednisolone sodium succinate, paramethasone acetate, prednisolone, prednisolone acetate, prednisolone hemisuccinate, prednisolone sodium phosphate, prednisolone sodium succinate, prednisolone tebutate, prednisone and triamcinolone, are employed as glucocorticosteroids.

4. Combination according to Claim 1, characterized in that beclomethasone or budesonide are employed as glucocorticosteroids.
5. Combination according to Claim 1 to 4, characterized in that compounds of the general formula



in which

- X and Y denote, identically or differently, sulphur, sulphoxide, sulphone, an alkylene chain, $-\text{SCH}_2-$ or oxygen or a direct linkage,
- W denotes $-\text{CH}=\text{CH}-$ or $-\text{CH}_2-\text{CH}_2-$,
- o denotes a number from 1 to 5,
- A and B denote, identically or differently, carboxyl, carboxymethyl, tetrazolyl or tetrazolylmethyl or $-\text{CO}_2\text{R}^9$ or $-\text{CH}_2\text{CO}_2\text{R}^9$ or $-\text{CONR}^{10}\text{R}^{11}$ or cyano,
- n denotes a number from 1 to 10,

m denotes a number from 0 to 7,

T and Z denote, identically or differently, oxygen or a direct linkage, and

R^2 , R^2 , R^8 denote, identically or differently, hydrogen, alkyl, alkoxy, halogen, trifluoromethyl, trifluoromethoxy, cyano or nitro,


5 R^9 denotes lower alkyl and

R^{10} and R^{11} denote hydrogen, lower alkyl, alkylsulphonyl or arylsulphonyl, or they form together an alkylene chain to form a ring,

and the salts thereof,

are employed as LTD₄ receptor antagonists.

- 10 6. Combination according to Claim 1 to 4, characterized in that a compound of the formula



in which

R^1 and R^2 are identical or different,

- 15 is employed as LTD₄ receptor antagonist.

7. Combination according to Claim 1 to 6, characterized in that the ratio of glucocorticosteroid to LTD₄ receptor antagonist can be combined in another ratio depending on the action potency of the individual substances.

8. Medicament containing the combinations according to Claim 1 to 7.

9. Use of combinations according to Claims 1 to 7 for producing medicaments.

INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP 96/04391

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 A61K31/19 A61K31/235 A61K31/57 //(A61K31/57,31:235,31:19)

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US,A,5 350 760 (LABELLE MARK ET AL) 27 September 1994 *cf. abstract, col. 16, lines 19-29* ---	1-9
X	US,A,5 360 815 (FORTIN REJEAN ET AL) 1 November 1994 *cf. abstract, col. 13, lines 39-49* ---	1-9
A	BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 3, no. 8, 1993, GREAT BRITAIN, pages 1517-1522, XP000650307 T.S. ABRAHAM ET AL.: "A new structural analogue antagonist of peptido-leukotrienes. The discovery of BAYX7195" cited in the application *cf. abstract* --- -/--	1-9

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

& document member of the same patent family

Date of the actual completion of the international search

23 January 1997

Date of mailing of the international search report

11.02.97

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Stoltner, A

INTERNATIONAL SEARCH REPORT

Int. onal Application No

PCT/EP 96/04391

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>CURRENT OPINION IN INVESTIGATIONAL DRUGS (EXPERT OPIN. INVEST. DRUGS), vol. 3, no. 2, February 1994, ABOIT LABORATORIES, ABOIT PARK, ILLINOIS USA, pages 185-190, XP000610416</p> <p>D.W. BROOKS: "Progress with investigational drugs for the treatment of pulmonary and inflammatory diseases"</p> <p>*cf. introduction and summary*</p> <p>---</p>	1-9
A	<p>PROSTAGLANDINS, vol. 50, no. 5-6, 1995, AVENUE OF THE AMERICAS, NEW YORK, pages 269-285, XP000611799</p> <p>H. TANAKA ET AL.: "The effect of a novel leukotriene C4/D4 antagonist, BAYx7195, on experimental allergic reactions"</p> <p>* introduction, discussion*</p> <p>-----</p>	1-9

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 96/04391

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US-A-5350760	27-09-94	AU-A- 7379794 CA-A- 2168668 WO-A- 9504741 EP-A- 0712407	28-02-95 16-02-95 16-02-95 22-05-96
US-A-5360815	01-11-94	CA-A- 2125830	24-12-94